$0.54 EPS Expected for Haemonetics Corporation (HAE)

October 13, 2018 - By Hugh Holland

Haemonetics Corporation (NYSE:HAE) LogoInvestors sentiment increased to 1.24 in Q2 2018. Its up 0.06, from 1.18 in 2018Q1. It is positive, as 25 investors sold Haemonetics Corporation shares while 84 reduced holdings. 64 funds opened positions while 71 raised stakes. 46.74 million shares or 6.30% less from 49.88 million shares in 2018Q1 were reported.
Bank & Trust Of New York Mellon stated it has 0.02% of its portfolio in Haemonetics Corporation (NYSE:HAE). Boston Partners holds 0% or 20,005 shares in its portfolio. Segall Bryant & Hamill Lc, Illinois-based fund reported 38,368 shares. Dimensional Fund L P reported 1.44M shares. Amg Bancorp holds 8,308 shares. Profund Advsrs Ltd Liability Corporation invested in 0.03% or 8,261 shares. Baldwin Brothers Ma holds 0.18% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 12,736 shares. Millennium Ltd Liability Corporation reported 229,949 shares. American Century Cos reported 0.03% of its portfolio in Haemonetics Corporation (NYSE:HAE). Clarivest Asset Limited Company owns 43,489 shares or 0.07% of their US portfolio. Parametric Portfolio Associate Ltd Llc reported 234,034 shares. Principal Fincl Group Inc Incorporated stated it has 256,154 shares. Eulav Asset reported 11,500 shares or 0.05% of all its holdings. First Quadrant Limited Partnership Ca stated it has 102,156 shares or 0.17% of all its holdings. Picton Mahoney Asset Mgmt invested in 168,800 shares.

Since June 6, 2018, it had 0 insider buys, and 10 insider sales for $5.73 million activity. 3,794 shares were sold by Goldstein Dan, worth $360,766 on Wednesday, June 6. Another trade for 30,824 shares valued at $3.45 million was made by GRANADILLO PEDRO P on Monday, September 17. Scanlan Jacqueline also sold $19,844 worth of Haemonetics Corporation (NYSE:HAE) shares. $179,989 worth of Haemonetics Corporation (NYSE:HAE) was sold by Simon – Christopher on Thursday, June 7. The insider Basil Michelle L sold $42,378. Another trade for 183 shares valued at $16,970 was made by Ryding Neil Mr. on Thursday, June 7.

Analysts expect Haemonetics Corporation (NYSE:HAE) to report $0.54 EPS on November, 6.They anticipate $0.06 EPS change or 12.50 % from last quarter’s $0.48 EPS. HAE’s profit would be $27.91M giving it 49.30 P/E if the $0.54 EPS is correct. After having $0.59 EPS previously, Haemonetics Corporation’s analysts see -8.47 % EPS growth. The stock increased 0.08% or $0.08 during the last trading session, reaching $106.48. About 711,724 shares traded or 34.45% up from the average. Haemonetics Corporation (NYSE:HAE) has risen 158.45% since October 14, 2017 and is uptrending. It has outperformed by 142.83% the S&P500.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Among 2 analysts covering Haemonetics (NYSE:HAE), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Haemonetics had 3 analyst reports since May 9, 2018 according to SRatingsIntel. Morgan Stanley maintained it with “Overweight” rating and $100 target in Wednesday, May 9 report. Jefferies maintained the stock with “Buy” rating in Thursday, June 14 report. The firm earned “Overweight” rating on Wednesday, August 8 by Morgan Stanley.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $5.50 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It has a 248.79 P/E ratio. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Haemonetics Corporation (NYSE:HAE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>